CASE REPORT article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1645909
This article is part of the Research TopicThe Role of Immunotherapy in Cancer Therapy and Its ChallengeView all articles
Case Report: The Integration of Chemoradiotherapy and Immunotherapy in a Patient with Advanced-Stage Renal Squamous Cell Carcinoma and Pulmonary Metastases
Provisionally accepted
- 1Hubei University of Medicine, Shiyan, China
- 2Taihe Hospital Department of Clinical Oncology, Shiyan, China
- 3Key Laboratory of Cancer Therapy Resistance and Clinical Translational Study, shiyan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Renal squamous cell carcinoma (RSCC) is an uncommon malignancy, representing less than 1% of all renal cancers, and is associated with a notably poor prognosis. Surgical intervention is the primary treatment modality for early and intermediate-stage cases; however, the efficacy of combined chemoradiotherapy and immunotherapy in advanced-stage patients remains unclear. In this report, we present a case of RSCC with pulmonary metastases，wherein the patient attained disease remission following a treatment regimen comprising combined chemo-radiotherapy and immunotherapy. The patient demonstrated a progression-free survival (PFS) of 12 months and an overall survival (OS) of 14 months.This case study aims to provide a comprehensive analysis of the treatment approach, potentially serving as a reference for therapeutic strategies in patients with inoperable RSCC.
Keywords: Renal squamous cell carcinoma, Pulmonary metastases, Immunotherapy, Radiotherapy, chemotherapy
Received: 12 Jun 2025; Accepted: 21 Jul 2025.
Copyright: © 2025 Niu, Wang, Deng, Luo, Chai and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Ming Luo, Taihe Hospital Department of Clinical Oncology, Shiyan, China
Jingjing Chai, Taihe Hospital Department of Clinical Oncology, Shiyan, China
Zhiguo Luo, Taihe Hospital Department of Clinical Oncology, Shiyan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.